Abstract | AIMS: METHODS AND RESULTS: We retrospectively included 100 consecutive ARVC patients who received flecainide with beta-blockers between May 1999 and November 2017. Treatment persistence and related side effects were assessed, as was VA-free survival on treatment, 24-h Holter monitoring and programmed ventricular stimulation (PVS) off- and on-treatment. Tolerance was good, with 10% flecainide discontinuations (lack of efficacy in six, atrial fibrillation in one, and side effects in three). No Brugada-induced electrocardiography pattern on flecainide or haemodynamic impairment was reported. Premature ventricular contraction burden at 24-h Holter monitoring was significantly decreased under treatment [median 415 (interquartile range, IQR 97-730) vs. 2370 (1572-3400) at baseline, P < 0.0001, n = 46]. Among the 33 patients with PVS under treatment, PVS was positive in 40% on-treatment vs. 94% off-treatment (P < 0.001). During a median follow-up of 47 months (IQR 23-73), 22 patients presented sustained VA on treatment, corresponding to an event rate of 5% [95% confidence interval (CI) (0.6-9)] at 1 year and 25% [95% CI (14-35)] at 5 years under treatment. No patient died. CONCLUSION:
|
Authors | Thomas Rolland, Nicolas Badenco, Carole Maupain, Guillaume Duthoit, Xavier Waintraub, Mikael Laredo, Caroline Himbert, Robert Frank, Francoise Hidden-Lucet, Estelle Gandjbakhch |
Journal | Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
(Europace)
Vol. 24
Issue 2
Pg. 278-284
(02 02 2022)
ISSN: 1532-2092 [Electronic] England |
PMID | 34459901
(Publication Type: Journal Article)
|
Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: [email protected]. |
Chemical References |
|
Topics |
- Arrhythmogenic Right Ventricular Dysplasia
(complications, diagnosis, drug therapy)
- Atrial Fibrillation
(drug therapy)
- Defibrillators, Implantable
- Flecainide
(adverse effects)
- Humans
- Retrospective Studies
- Sotalol
- Tachycardia, Ventricular
(complications, diagnosis, drug therapy)
- Treatment Outcome
|